[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JPH0434555B2 - - Google Patents

Info

Publication number
JPH0434555B2
JPH0434555B2 JP18842383A JP18842383A JPH0434555B2 JP H0434555 B2 JPH0434555 B2 JP H0434555B2 JP 18842383 A JP18842383 A JP 18842383A JP 18842383 A JP18842383 A JP 18842383A JP H0434555 B2 JPH0434555 B2 JP H0434555B2
Authority
JP
Japan
Prior art keywords
ail
formula
compound
compound represented
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP18842383A
Other languages
Japanese (ja)
Other versions
JPS6081184A (en
Inventor
Daisuke Kamimura
Shuichi Iwadare
Takashi Mitomo
Fumio Nakano
Akinori Matsuzaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Original Assignee
Banyu Phamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Phamaceutical Co Ltd filed Critical Banyu Phamaceutical Co Ltd
Priority to JP18842383A priority Critical patent/JPS6081184A/en
Publication of JPS6081184A publication Critical patent/JPS6081184A/en
Publication of JPH0434555B2 publication Critical patent/JPH0434555B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は、抗菌活性及び抗腫瘍活性を有する一
般式 (式中Rは水素原子又は低級アルカノイル基を示
す)で表わされる新規な化合物及びその製法に関
する。 本発明者らは愛知県岡崎市の土壌より新たに分
離された菌株(以下Y−32026と呼ぶ)が抗菌性
及び抗腫瘍性を有する物質を生産することを見出
し、培養から次式 で示される新規化合物(AIL)を分離することに
成功した(特開昭58−150595号公報参照)。そし
てさらにこの培養物を精査した結果、化合物AIL
の他に新規化合物であるAIL−Bを見出した。 式Iにおいて置換基Rが水素原子である化合物
AIL−Bは、下記の物理化学的性質を有する。 分子式:34H47N3O9 分子量:641 マススペクトル(FDMS):m/e664(M++Na) IR(CHCl3)吸収:3200、1765、1655、1507、
1410、1190、980cm-1 UV吸収:λCH3OH max230、265(sh)、275、285
(sh)nm1 HNMR(CDCl3+CD3OD):δ 0.97(3H、d、
J=5.6Hz)、1.07(3H、s)、1.20(1H、m)、
1.25(3H、d、J=7.3Hz)、1.32(3H、s)、
1.73(1H、m)、1.77(3H、s)、2.08(1H、m)、
2.48(1H、q、J=7.3Hz)、2.86(3H、s)、
3.52(2H、d、J=7.3Hz)、3.85〜3.95(3H、
m)、3.93(2H、s)、4.34(1H、dd、J=7.0&
6.3Hz)、4.63(1H、s)、5.63(1H、dd、J=7.0
&14.9Hz)、5.67(1H、dt、J=6.3&14.4Hz)、
5.77)1H、dt、J=7.3&15.2Hz)、5.95(1H、
dd、J=11.9&11.9Hz)、6.16(1H、dd、J=
10.6&14.4Hz)、6.21(1H、dd、J=10.6&14.9
Hz)、6.21(1H、dd、J=11.9Hz)、6.41(1H、
brd、J=11.9Hz)、6.64(1H、dd、J=11.9&
15.2Hz)、6.80(1H、s)、7.00(1H、brt、J=
5.6Hz)、7.84(1H、s)13 CNMR(CD3OD):δ 11.408(q)、17.726
(q)、19.656(q)21.470(q)、23.108(d)、
24.278(d)、26.092(q)、29.017(t)、36.096
(t)、42.765(q)、45.164(t)、45.339(s)、
58.151(t)、72.192(s)、75.234(d)、76.814(d)、
80.792(s)、87.461(d)、122.270(d)、124.025(d)、
124.845(d)、128.121(d)、128.530(d)、129.291(d)、
129.583(d)、130.870(d)、131.338(d)、134.556(d)、
138.534(s)、150.703(d)、151.112(s)、
171.764(s)、176.035(s)、178.433(s) 本発明の一般式(I)の化合物中、置換基Rが
低級アルカノイル基である化合物、即ち一般式
(−b)の化合物は、構造式(−a)の化合
物(以下、AIL−Bと略す)をピリジンの存在下
に、酸無水物と反応させて、低級アルカノイル化
することにより製造でき、通常、ベンゼン、アセ
トン、酢酸エチル等の反応に悪影響を及ぼさない
溶媒にAIL−Bを溶解し、過剰のピリジン等のア
ミンの存在下、過剰の酸無水物を反応させる。 この場合、ピリジン等のアミンを反応溶媒とす
ることができる。該反応は室温で進行し、数時間
程度で完結する。反応終了後、過剰のアミンおよ
び酸無水物を留去したのち、例えばシリカゲルカ
ラムクロマト等の公知の精製分離方法により、一
般式(−b)の化合物を得ることができる。 低級アルガノイル基としては、アセチル基プロ
ピオニル基、ブチリル基、イソブチリル基、ピバ
ロイル基等が挙げられ、特にアセチル基が好まし
い。 該酸無水物としては、無水酢酸、無水プロピオ
ン酸、無水酪酸、無水イソ酪酸等の酸無水物が挙
げられる。 例えば、一般式(I)において、置換基Rが、
アセチル基である化合物(AIL−Bトリアセテー
ト)は、AIL−Bをピリジンの存在下に無水酢酸
を作用させることによつて製造される。 AIL−Bをメタノール中、−78℃でオゾン酸化
し、生じたオゾナイドを水素化硼素ナトリウムで
還元し、得られたアルコールを無水酢酸−ピリジ
ンでアセチル化すると分解物(と)が得られ
る。 分解物はAILを同様にオゾン分解に付して得
られた分解物と完全に一致した。以上の事実によ
りAIL−Bは式(−a)で示される構造を有す
ることが明らかになつた。 AIL−Bは、ストレプトミセス属に属するAIL
−B生産菌を培養し、培養液からAIL−Bを採取
することにより得られる。 AIL−Bを製造するには、ストレプトミセス属
に属するAIL−Bを生産する能力を有する菌株を
用いることができる。特に本発明者らにより分離
された菌株Y−3026、又はその変異株を用いるこ
とが好ましい。Y−32026株は工業技術院微生物
工業技術研究所に微工研菌寄第6313号(FERM
P−6313)として寄託されている。 その菌学的性状は、特記しない限り28℃で14日
間観察しもので、次のとおりである。 (1) 形態的性状 分岐した基生菌糸から0.6〜0.7μmの気中菌
糸が伸長し、直線状又は屈曲状を示す。成熟し
た培養物の気中菌糸を検鏡すると卵形の胞子1
×1μmが連鎖状1〜10個になつているものは
少なく、主として大きさ不揃い柱筒状0.4〜
1.0μm×0.7〜3μmの分節胞子様5〜30個の連
鎖が気中菌糸上で観察された。 すなわち、胞子柄上に着生する胞子数は1〜
2個で、それに連続する分節胞子が直線状でな
く不揃いの点はシユードノカルデイアの特徴を
有し、また頂生胞子と内生胞子が見られる場合
がありアクチノマデユーラの特徴も散見され
た。 他に特殊な器官の形成は認められなかつた。 (2) 菌体組成 本菌株をロマノ及びソーラー(Romano
and Sohler)の改変培地中で、28℃で72時間
振盪培養したのち、集菌洗浄した。この菌体を
ジヤーナル・オブ・バクチリオロジー89巻2号
44〜453頁1965年に記載の山口らの方法に従つ
て分析実験し、L,L―ジアミノピメリン酸及
びグリシンを認めた。 この結果をレシバリエ(Lechevalier)によ
る科及び属の検索式(ザ・バイオロジー・オ
ブ・ジアクチノミセテス・アンド・リレイテツ
ド・オーガニスムス11巻78〜92頁1976年)に適
用すると、細胞壁組成型―ストレプトミセス
属に該当した。 (3) 培養的性状 各種培地上で28℃で10〜14日間培養して観察
した結果は、第1表に示すとおりである。
The present invention provides a general formula that has antibacterial and antitumor activity. The present invention relates to a novel compound represented by the formula (in which R represents a hydrogen atom or a lower alkanoyl group) and a method for producing the same. The present inventors discovered that a newly isolated bacterial strain (hereinafter referred to as Y-32026) from the soil of Okazaki City, Aichi Prefecture, produces a substance with antibacterial and antitumor properties. We succeeded in isolating a new compound (AIL) represented by (see Japanese Patent Application Laid-Open No. 150595/1983). Further examination of this culture revealed that the compound AIL
In addition, a new compound, AIL-B, was discovered. Compounds of formula I in which substituent R is a hydrogen atom
AIL-B has the following physicochemical properties. Molecular formula: 34 H 47 N 3 O 9 Molecular weight: 641 Mass spectrum (FDMS): m/e664 (M + +Na) IR (CHCl 3 ) absorption: 3200, 1765, 1655, 1507,
1410, 1190, 980cm -1 UV absorption: λCH 3 OH max230, 265 (sh), 275, 285
(sh) nm 1 HNMR (CDCl 3 + CD 3 OD): δ 0.97 (3H, d,
J=5.6Hz), 1.07 (3H, s), 1.20 (1H, m),
1.25 (3H, d, J=7.3Hz), 1.32 (3H, s),
1.73 (1H, m), 1.77 (3H, s), 2.08 (1H, m),
2.48 (1H, q, J = 7.3Hz), 2.86 (3H, s),
3.52 (2H, d, J = 7.3Hz), 3.85-3.95 (3H,
m), 3.93 (2H, s), 4.34 (1H, dd, J=7.0&
6.3Hz), 4.63 (1H, s), 5.63 (1H, dd, J=7.0
&14.9Hz), 5.67 (1H, dt, J=6.3&14.4Hz),
5.77) 1H, dt, J = 7.3 & 15.2Hz), 5.95 (1H,
dd, J=11.9 & 11.9Hz), 6.16(1H, dd, J=
10.6 & 14.4Hz), 6.21 (1H, dd, J = 10.6 & 14.9
Hz), 6.21 (1H, dd, J=11.9Hz), 6.41 (1H,
brd, J=11.9Hz), 6.64(1H, dd, J=11.9&
15.2Hz), 6.80 (1H, s), 7.00 (1H, brt, J=
5.6Hz), 7.84 (1H, s) 13 CNMR (CD 3 OD): δ 11.408 (q), 17.726
(q), 19.656 (q) 21.470 (q), 23.108 (d),
24.278(d), 26.092(q), 29.017(t), 36.096
(t), 42.765 (q), 45.164 (t), 45.339 (s),
58.151(t), 72.192(s), 75.234(d), 76.814(d),
80.792(s), 87.461(d), 122.270(d), 124.025(d),
124.845(d), 128.121(d), 128.530(d), 129.291(d),
129.583(d), 130.870(d), 131.338(d), 134.556(d),
138.534(s), 150.703(d), 151.112(s),
171.764(s), 176.035(s), 178.433(s) Among the compounds of the general formula (I) of the present invention, the compound in which the substituent R is a lower alkanoyl group, that is, the compound of the general formula (-b), has the structural formula It can be produced by reacting the compound (-a) (hereinafter abbreviated as AIL-B) with an acid anhydride in the presence of pyridine to convert it into lower alkanoylation, and is usually produced by reaction with benzene, acetone, ethyl acetate, etc. AIL-B is dissolved in a solvent that does not have an adverse effect on the AIL-B, and excess acid anhydride is reacted in the presence of an excess amine such as pyridine. In this case, an amine such as pyridine can be used as a reaction solvent. The reaction proceeds at room temperature and is completed in about several hours. After completion of the reaction, excess amine and acid anhydride are distilled off, and then the compound of general formula (-b) can be obtained by a known purification and separation method such as silica gel column chromatography. Examples of the lower arganoyl group include an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a pivaloyl group, and an acetyl group is particularly preferred. Examples of the acid anhydride include acid anhydrides such as acetic anhydride, propionic anhydride, butyric anhydride, and isobutyric anhydride. For example, in general formula (I), the substituent R is
A compound having an acetyl group (AIL-B triacetate) is produced by reacting AIL-B with acetic anhydride in the presence of pyridine. AIL-B is oxidized with ozone in methanol at -78°C, the resulting ozonide is reduced with sodium borohydride, and the resulting alcohol is acetylated with acetic anhydride-pyridine to obtain a decomposition product (and). The decomposition products were completely identical to those obtained by subjecting AIL to ozonolysis. The above facts revealed that AIL-B has a structure represented by formula (-a). AIL-B is an AIL belonging to the genus Streptomyces.
-AIL-B can be obtained by culturing B-producing bacteria and collecting AIL-B from the culture solution. In order to produce AIL-B, a strain belonging to the genus Streptomyces that has the ability to produce AIL-B can be used. In particular, it is preferable to use strain Y-3026 isolated by the present inventors or a mutant strain thereof. Strain Y-32026 was submitted to the Institute of Microbiology, Agency of Industrial Science and Technology with Microbiological Research Institute No. 6313 (FERM).
P-6313). The mycological properties were observed at 28°C for 14 days unless otherwise specified, and are as follows. (1) Morphological characteristics Aerial hyphae of 0.6 to 0.7 μm extend from the branched basal hyphae and exhibit a straight or curved shape. When the aerial hyphae of a mature culture are examined under a microscope, 1 oval spore is found.
There are few cases in which 1 to 10 pieces of ×1 μm are connected in a chain shape, and mainly cylindrical shapes with irregular sizes of 0.4 to 1 μm.
Chains of 5 to 30 segmented spores of 1.0 μm x 0.7 to 3 μm were observed on the aerial hyphae. In other words, the number of spores that settle on the sporophyte is 1 to 1.
If there are two, and the consecutive segmental spores are not linear but irregular, it has the characteristics of Sciudonochaldeia, and acrospores and endospores may be seen, and there are also characteristics of Actinomadeula. It was done. No other special organs were observed. (2) Bacterial composition This strain was used as Romano and Solar (Romano
After culturing with shaking at 28°C for 72 hours in a modified medium of J.D. and Sohler), the cells were collected and washed. Journal of Bacteriology Vol. 89 No. 2
An analytical experiment was performed according to the method of Yamaguchi et al., described on pages 44-453 in 1965, and L,L-diaminopimelic acid and glycine were detected. When this result is applied to the family and genus search formula by Lechevalier (The Biology of Diactinomycetes and Related Organisms, Vol. 11, pp. 78-92, 1976), cell wall composition types - It belonged to the genus Streptomyces. (3) Cultural properties Table 1 shows the results of culturing on various media at 28°C for 10 to 14 days.

【表】【table】

【表】 (4) 生理的性状 (1) 生育温度範囲:15〜37℃(至適温度25〜30
℃) (2) ゼラチンの液化:陽性 (3) 殿粉の加水分解:陽性 (4) 脱脂乳のペプトン化:陽性 凝固化:陰性 (5) メラニン様色素の生成 チロシン寒天培地:陽性 ペプトン・イースト鉄寒天培地:陰性 (6) 炭素源の同化性(プリドハム・ゴツトリー
ブ寒天を使用)は第2表のとおりである。
[Table] (4) Physiological properties (1) Growth temperature range: 15-37℃ (optimum temperature 25-30℃)
(℃) (2) Liquefaction of gelatin: Positive (3) Hydrolysis of starch: Positive (4) Peptonization of skim milk: Positive Coagulation: Negative (5) Production of melanin-like pigment Tyrosine agar medium: Positive Peptone yeast Iron agar medium: Negative (6) Assimilation of the carbon source (using Pridham-Gottlieb agar) is as shown in Table 2.

【表】 −:発育しない
(5) その他の諸性状 液体培地で通気培養した本菌株は、斜面寒天
培養時の形態と全く相違して、対数増殖期には
全部が桿菌状を呈した。 また、本菌株の栄養菌糸をグラム染色すると
陽性であつた。 以上述べたようにY−32026株は、液体培養
で桿菌状の増殖を示すと共に、胞子形態の電顕
像ではシユードノカルデイア及びアクチノマデ
ユーラに類縁性があるが、培養生理的には炭素
源の資化性が広く、気菌糸が豊富でメラニン様
色素を生成し、細胞壁組成が型であることか
ら、本菌株はストレプトミセス属に属すると同
定された(インターナシヨナル・ジヤーナル・
オブ・システマチツク・バクテリオロジー26巻
4号1976年、21巻1号1971年、アプライド・マ
イクロバイオロジー13巻2号1965年及びバージ
ーズ・マニユアル・オブ・デターミナテイブ・
バクテラオロジー第8版1974年参照)。 AIL−Bを発酵法により製造するには、通常の
ストレプトミセスの培養法を用いることができ、
発酵槽内で通気撹拌培養することが好適である。 培地には各種炭素源、窒素源、無機物、生長促
進剤、生長抑制剤、消泡剤等を適当に組み合わせ
て用いることができる。炭素源としては澱粉グリ
セリン、グルコース、マンノース、フラクトー
ス、シユークロース、糖蜜等が単独で又は組み合
わせて用いられる。無機又は有機の窒素源として
は塩化アンモン、硫酸アンモン、硝酸アンモン、
硝酸ソーダ、尿素、ペプトン、肉エキス、酵母エ
キス、乾燥酵母、コーンスチープリカー、大豆粉
等が単独で又は組み合わせて用いられる。そのほ
か必要に応じて食塩、塩化カリウム、カルシウム
塩、リン酸塩、鉄塩、銅塩、亜鉛塩、、マンガン
塩、コバルト塩、マグネシウム塩等の無機塩を加
えることもできる。 培養温度は一般に20〜40℃で、特に27〜30℃が
好ましい。培地のPHは、通常用いられる酸又は塩
基を必要に応じて添加し、PH4〜10、好ましくは
PH6〜8に調整する。通気下に1〜4日間培養す
ると、AIL−Bが菌体内及び培養液中に蓄積され
る。生産量が最大に達した時点で培養を停止し、
培養液を過し、湿菌体と培養液に分離する。 単離精製には通常の方法を用いる。分離した菌
体は例えばアセトン、酢酸エチル、酢酸ブチル等
の溶媒中で撹拌下に機械的に粉砕し、抽出する。
液は酢酸エチル又は酢酸ブチルで撹拌下に抽出
する。菌体からの抽出液及び培養液からの抽出
液を一緒にあるいは別個に濃縮し、必要な場合、
特に湿菌体をアセトンで抽出した場合は、水を含
む濃縮残渣を再度酢酸ブチル、酢酸エチル等で抽
出し、濃縮し、夫々の濃縮残渣を一緒に、あるい
は別個にシリカゲルカラムに吸着させ、適当な溶
媒、例えばクロロホルムーメタノール系の溶媒
で、その混合比を変えて徐々に極性を増しながら
溶離を行うと、AILが溶離した直後にAIL−Bが
溶離してくる。目的物を含むフラクシヨンをまと
めて濃縮することにより、AIL−Bを得ることが
できる。このものはシリカゲルプレートいキーゼ
ルゲル60F254、メルク社製)を用い、15%のメタ
ノールを含むクロロホルムを展開溶媒とし硫酸あ
るいは紫外線を発色剤とした薄層クロマトグラフ
イー(TLC)でAILはRf値0.60、AIL−BはRf値
0.58を示し、またS.ルテアを用いたバイオオート
グラフイーでも同じRf値の坑菌スポツトを示し
た。 本発明の化合物AIL−Bは腹腔内投与で、マウ
スのエールリツヒ腹水癌に対して延命効果を示し
た。 実施例 1 可溶性澱粉15g/、大豆粉15g/、
K2HPO41g/、MgSO4・7H2Oの0.5g/、
NaCl1g/及びCaCl0.5g/の水性培地(PH
7)に、Y−32026株を植菌し、28℃で30時間シ
エカーで振盪培養した。 得られた種培養液を200のタンク中で、下記
組成の発酵培地140に移液し、28℃で43時間、
通気撹拌下(130/分、200rpm)に培養した。 発酵培地組成:グリセリン2.0%、ペプトン10%、
肉エキス0.5%、NaCl0.1%、K2HPO40.1%、
MgSO4・7H2O0.05%、CaCl2・2H2O0.05% 培養液を過し、液約125と湿菌体約5.2Kg
を得た。液をPH7で酢酸ブチル60で2回抽出
し、Na2SO4で乾燥したのち、減圧で溶媒を留去
し、残渣をワコーゲルC−200(和光純薬製カラム
クロマト用シリカゲル)300gのカラムに吸着さ
せ、0.5%、1%、2%、3%、5%、10%のメ
タノールークロロホルム各1.2で順に、TLCで
モニターしながら溶出させ、目的物を含むフラク
シヨンを集め、減圧で溶媒を留去して、AIL−
B20mgを得た。 実地例 2 実施例1で得たAIL−B5mgをピリジン0.5mlに
溶解し、冷却下に無水酢酸0.5mlを加えて室温で
一晩放置したのち、真空でピリジン一無水酢酸を
留去し、さらにトルエンを加えて共沸で完全に除
き、AIL−Bトリアセテート5mgを得た。 物理化学的データー:NMRスペクトルにおい
て、AIL−Bでδ3.93にみられたCH2OHのシング
レツトピークは、アセチル化されることにより底
磁場シフト受け、δ4.20とδ4.66にABq(J=12.5
Hz)として観測された。
[Table] −: Not growing
(5) Other properties The morphology of this strain cultured in a liquid medium through aeration was completely different from that when cultured on slanted agar, and all of the strains exhibited a rod-like shape during the logarithmic growth phase. In addition, Gram staining of the vegetative hyphae of this strain was positive. As mentioned above, strain Y-32026 exhibits bacillary growth in liquid culture, and the electron microscopic image of the spore form shows that it is related to S. This strain was identified as belonging to the genus Streptomyces because of its ability to assimilate carbon sources, have abundant aerial hyphae, produce melanin-like pigments, and have a typical cell wall composition.
of Systematic Bacteriology, Vol. 26, No. 4, 1976; Vol. 21, No. 1, 1971; Applied Microbiology, Vol. 13, No. 2, 1965;
(See Bacterology 8th edition 1974). To produce AIL-B by fermentation, a normal Streptomyces culture method can be used.
It is preferable to culture with aeration in a fermenter. Various carbon sources, nitrogen sources, inorganic substances, growth promoters, growth inhibitors, antifoaming agents, etc. can be used in appropriate combinations in the culture medium. As the carbon source, starch glycerin, glucose, mannose, fructose, sucrose, molasses, etc. are used alone or in combination. Inorganic or organic nitrogen sources include ammonium chloride, ammonium sulfate, ammonium nitrate,
Sodium nitrate, urea, peptone, meat extract, yeast extract, dry yeast, corn steep liquor, soybean flour, etc. may be used alone or in combination. In addition, inorganic salts such as common salt, potassium chloride, calcium salts, phosphates, iron salts, copper salts, zinc salts, manganese salts, cobalt salts, magnesium salts, etc. can be added as necessary. The culture temperature is generally 20 to 40°C, particularly preferably 27 to 30°C. The pH of the medium is adjusted to 4 to 10, preferably by adding a commonly used acid or base as necessary.
Adjust the pH to 6-8. When cultured for 1 to 4 days under aeration, AIL-B accumulates within the bacterial cells and in the culture solution. Stop the culture when the maximum production amount is reached,
The culture solution is filtered and separated into wet bacterial cells and culture solution. Conventional methods are used for isolation and purification. The separated bacterial cells are mechanically crushed and extracted in a solvent such as acetone, ethyl acetate, butyl acetate, etc. while stirring.
The liquid is extracted with ethyl acetate or butyl acetate while stirring. Concentrate the extract from the bacterial cells and the extract from the culture solution together or separately, and if necessary,
In particular, when wet bacterial cells are extracted with acetone, the concentrated residue containing water is extracted again with butyl acetate, ethyl acetate, etc., concentrated, and each concentrated residue is adsorbed together or separately on a silica gel column, and then When elution is performed using a solvent such as chloroform-methanol, while gradually increasing the polarity by changing the mixing ratio, AIL-B elutes immediately after AIL elutes. AIL-B can be obtained by collectively concentrating the fractions containing the target product. This is thin layer chromatography (TLC) using a silica gel plate (Kieselgel 60F 254 , manufactured by Merck & Co.), chloroform containing 15% methanol as a developing solvent, and sulfuric acid or ultraviolet light as a coloring agent. AIL has an Rf value of 0.60. , AIL-B is the Rf value
0.58, and bioautography using S. lutea also showed antibacterial spots with the same Rf value. The compound AIL-B of the present invention showed a survival effect on Ehrlichi's ascites carcinoma in mice when administered intraperitoneally. Example 1 Soluble starch 15g/, soybean flour 15g/,
K 2 HPO 4 1g/, MgSO 4・7H 2 O 0.5g/,
Aqueous medium (PH
7) was inoculated with strain Y-32026 and cultured with shaking in a shaker at 28°C for 30 hours. The obtained seed culture solution was transferred to fermentation medium 140 with the following composition in a tank of 200, and incubated at 28°C for 43 hours.
Culture was carried out under aeration and stirring (130/min, 200 rpm). Fermentation medium composition: glycerin 2.0%, peptone 10%,
Meat extract 0.5%, NaCl 0.1%, K2HPO4 0.1 %,
MgSO 4・7H 2 O 0.05%, CaCl 2・2H 2 O 0.05% The culture solution is filtered, and the liquid is about 125% and the wet bacterial cells are about 5.2Kg.
I got it. The liquid was extracted twice with butyl acetate 60 at pH 7, dried over Na 2 SO 4 , and the solvent was distilled off under reduced pressure. Adsorb and elute with 0.5%, 1%, 2%, 3%, 5%, 1.2% each of methanol and chloroform in order while monitoring with TLC. Fractions containing the target product are collected and the solvent is distilled off under reduced pressure. Leave, AIL-
Obtained 20mg of B. Practical example 2 5 mg of AIL-B obtained in Example 1 was dissolved in 0.5 ml of pyridine, 0.5 ml of acetic anhydride was added under cooling, and the mixture was allowed to stand at room temperature overnight. Pyridine monoacetic anhydride was distilled off in vacuo, and further Toluene was added and completely removed azeotropically to obtain 5 mg of AIL-B triacetate. Physicochemical data: In the NMR spectrum, the CH 2 OH singlet peak observed at δ3.93 in AIL-B undergoes a bottom magnetic field shift due to acetylation, and ABq ( J=12.5
Hz).

【図面の簡単な説明】[Brief explanation of drawings]

第1図は抗腫瘍性抗生物質AIL−Bの赤外線吸
収スペクトル、、第2図は抗腫瘍性抗生物質AIL
−Bの紫外線吸収スペクトルである。
Figure 1 is the infrared absorption spectrum of anti-tumor antibiotic AIL-B, Figure 2 is the anti-tumor antibiotic AIL
-B is an ultraviolet absorption spectrum.

Claims (1)

【特許請求の範囲】 1 一般式 (式中Rは水素原子又は低級アルカノイル基を示
す)で表される化合物。 2 Rが水素原子である特許請求の範囲第1項記
載の化合物。 3 Rがアセチル基である特許請求の範囲第1項
記載の化合物。 4 構造式 で表される化合物を製造するにあたり、ストレプ
トミセス属に属し、構造式(I−a)の化合物を
生産する能力を有する微生物を培養し、その培養
液および菌体より構造式(I−a)の化合物を採
取することを特徴とする、構造式(I−a)で表
される化合物の製法。 5 構造式(I−a)の化合物を酸無水物と反応
させることを特徴とする、一般式(I−b) (式中R1は低級アルカノイル基を示す)で表さ
れる化合物の製法。 6 酸無水物が無水酢酸であり、かつR1がアセ
チル基である、特許請求の範囲第5項記載の方
法。
[Claims] 1. General formula A compound represented by (wherein R represents a hydrogen atom or a lower alkanoyl group). 2. The compound according to claim 1, wherein R is a hydrogen atom. 3. The compound according to claim 1, wherein R is an acetyl group. 4 Structural formula In producing the compound represented by the formula (I-a), a microorganism belonging to the genus Streptomyces and having the ability to produce the compound of the structural formula (I-a) is cultured, and from the culture solution and bacterial cells, the compound represented by the structural formula (I-a) is obtained. A method for producing a compound represented by structural formula (I-a), which comprises collecting a compound represented by formula (I-a). 5 General formula (I-b) characterized by reacting the compound of structural formula (I-a) with an acid anhydride A method for producing a compound represented by (in the formula, R 1 represents a lower alkanoyl group). 6. The method according to claim 5, wherein the acid anhydride is acetic anhydride and R 1 is an acetyl group.
JP18842383A 1983-10-11 1983-10-11 Antitumor antibiotic substance and production thereof Granted JPS6081184A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP18842383A JPS6081184A (en) 1983-10-11 1983-10-11 Antitumor antibiotic substance and production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18842383A JPS6081184A (en) 1983-10-11 1983-10-11 Antitumor antibiotic substance and production thereof

Publications (2)

Publication Number Publication Date
JPS6081184A JPS6081184A (en) 1985-05-09
JPH0434555B2 true JPH0434555B2 (en) 1992-06-08

Family

ID=16223403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18842383A Granted JPS6081184A (en) 1983-10-11 1983-10-11 Antitumor antibiotic substance and production thereof

Country Status (1)

Country Link
JP (1) JPS6081184A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312339B2 (en) * 2003-06-13 2007-12-25 Thallion Pharmaceuticals Inc. Polyene oxazoles and processes for their preparation

Also Published As

Publication number Publication date
JPS6081184A (en) 1985-05-09

Similar Documents

Publication Publication Date Title
KR880002483B1 (en) Process for preparing 3-hydroxy-ml-236b derivatives
JPH04352783A (en) 12-membered ring macrolide compound
US4366247A (en) Process for preparing tylactone
JPH0434555B2 (en)
US4362881A (en) Tylactone
JP2592468B2 (en) Benanomycins A and B, novel antibiotics and their production
JP4439079B2 (en) Method for producing pravastatin
EP0083019A2 (en) Process for optically active anthracycline glycosides, the novel 4-deoxy-aclacinomycins A and B and pharmaceutical preparations
JP4342048B2 (en) Antibiotics tuberacutomycin B, D and E and methods for their production
CA1169795A (en) Microbial process for producing cholanic acid derivatives and microbes used therein
JPS6219599A (en) Novel macrolide antibiotic m119
JPH0625277A (en) Bacterium producing novel testosterone-5alpha-reductase-inhibiting substance, sna-4606, novel testosterone-5-reductase-inhibiting substance, sna-4606 and its production
JP2716728B2 (en) Novel microorganism and method for producing 9-keto 16-membered macrolide antibiotics
JPH03227971A (en) Carbazole compound
JP3327982B2 (en) New antibiotic MI481-42F4-A related substance
AU620595B2 (en) Process for the preparation of macrolide compounds
JP3067322B2 (en) Method for producing 3'-hydroxybenanomycin A, an antifungal antibiotic
JP2786267B2 (en) New substance DC116
JPS62186787A (en) Novel microorganism
JPH11217382A (en) Antibiotic tubelactomicin and its production
JPH0420438B2 (en)
JPH06105696A (en) Production of tylonolide derivative
JPH0462317B2 (en)
EP0061737A1 (en) Process for production of adriamycin
JPH10237091A (en) New antibiotic formamycin and its production